Health AI Central
Peer-Reviewed Publication
Abdom Radiol (NY)2026;51(10):5049-5057.October 1, 2026Journal Article

Quantitative CT Perfusion as a prognostic biomarker for chemotherapy response in patients with pancreatic ductal adenocarcinoma.

Tom Perik1, Geke Litjens2, Natalia Alves3, Ewoud J Smit3, Martijn W J Stommel4, Erwin van Geenen5, Henkjan Huisman3, John Hermans3
1Department of Medical Imaging, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. tom.perik@radboudumc.nl.
2Department of Gastroenterology and Hepatology, Isala, Zwolle, Netherlands.
3Department of Medical Imaging, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
4Department of Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
5Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
PubMed DOI

Abstract

BACKGROUND: Response evaluation of pancreatic ductal adenocarcinoma (PDAC) with routine contrast-enhanced CT (CECT) using RECIST is currently inadequate for identification of patients benefiting from chemotherapy treatment, as the majority of patients show stable disease. This might lead to inappropriate treatment and potentially diminishes patients' quality of life. Recent developments in CT perf…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.